Lung cancer patients with mutations in the EGFR gene represent a
significant amount of patients diagnosed with non-small cell lung cancer.
Approximately 10-15% of patients with non-small cell lung cancer in the
United States and 35% in Asia have an EGFR positive mutation. In the U.S., more
than 20,000 people are diagnosed with EGFR positive lung cancer each
EGFR Resisters is comprised of over 1700 members from over 30 countries. Out
of the 65% of members who have provided data, 73% have already
developed acquired resistance to their current EGFR treatment. The types of
resistance mechanisms seen in this community are consistent with results
that have been published from other studies.
We are working to increase the size of our EGFR Resisters community with
the assistance of advocacy groups and medical professionals. Our aim is
to use the strength of our collaboration to drive important research
questions and fund novel research and clinical trials.